VTGN250117C7000
- 0.22
- 0.000.00%
VistaGen Therapeutics Newsroom
VistaGen Therapeutics Advances Neurocircuitry Treatments
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Vistagen to Present at the Stifel 2024 Healthcare Conference
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript Summary
VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges With a ...
Vistagen Therapeutics Reports Increased R&D Expenses
VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
VistaGen Therapeutics GAAP EPS of -$0.42 Misses by $0.03, Revenue of $0.18M Beats by $0.15M
VistaGen Therapeutics | 10-Q: Q2 2025 Earnings Report
Express News | Vistagen Therapeutics Inc - Qtrly Shr Loss $0.42
Earnings Flash (VTGN) VISTAGEN Reports Q2 Revenue $183M
Earnings Preview: VTGN to Report Financial Results Post-market on November 07
Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q1 2025 Earnings Conference